{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:40:52Z","timestamp":1789015252478,"version":"build-2803163510"},"reference-count":181,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T00:00:00Z","timestamp":1700956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterized by the presence of autoantibodies targeting BP180 and BP230 in the basement membrane zone. This leads to the activation of complement-dependent and independent pathways, resulting in proteolytic cleavage at the dermoepidermal junction and an eosinophilic inflammatory response. While numerous drugs have been associated with BP in the literature, causality and pathogenic mechanisms remain elusive in most cases. Dipeptidyl peptidase 4 inhibitors (DPP4i), in particular, are the most frequently reported drugs related to BP and, therefore, have been extensively investigated. They can potentially trigger BP through the impaired proteolytic degradation of BP180, combined with immune dysregulation. DPP4i-associated BP can be categorized into true drug-induced BP and drug-triggered BP, with the latter resembling classic BP. Antineoplastic immunotherapy is increasingly associated with BP, with both B and T cells involved. Other drugs, including biologics, diuretics and cardiovascular and neuropsychiatric agents, present weaker evidence and poorly understood pathogenic mechanisms. Further research is needed due to the growing incidence of BP and the increasing identification of new potential triggers.<\/jats:p>","DOI":"10.3390\/ijms242316786","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:32:03Z","timestamp":1701055923000},"page":"16786","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid"],"prefix":"10.3390","volume":"24","author":[{"given":"Belen","family":"de Nicolas-Ruanes","sequence":"first","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuncion","family":"Ballester-Martinez","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-8361","authenticated-orcid":false,"given":"Emilio","family":"Garcia-Mouronte","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-5421","authenticated-orcid":false,"given":"Emilio","family":"Berna-Rico","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Azcarraga-Llobet","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Fernandez-Guarino","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2020.11.076","article-title":"Subepithelial Autoimmune Blistering Dermatoses: Clinical Features and Diagnosis","volume":"85","author":"Montagnon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjd.20838","article-title":"Unfolding the Worldwide Incidence of Bullous Pemphigoid: What Are We Missing?","volume":"186","author":"Aoki","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case\u2013Control Study","volume":"131","author":"Joly","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3457","article-title":"A Systematic Review of Drug-Induced Pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous Pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous Pemphigoid and Pemphigus Vulgaris\u2014Incidence and Mortality in the UK: Population Based Cohort Study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Moro, F., Fania, L., Sinagra, J.L.M., Salemme, A., and Di Zenzo, G. (2020). Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules, 10.","DOI":"10.3390\/biom10101432"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K Guidelines for the Management of Bullous Pemphigoid Initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3389\/fimmu.2018.00479","article-title":"Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody","volume":"9","author":"Muller","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2013.07.009","article-title":"Comparative Study of Direct and Indirect Immunofluorescence and of Bullous Pemphigoid 180 and 230 Enzyme-Linked Immunosorbent Assays for Diagnosis of Bullous Pemphigoid","volume":"69","author":"Kostaki","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/ajd.13034","article-title":"A New Indirect Immunofluorescence BIOCHIP Method for the Serological Diagnosis of Bullous Pemphigoid: A Review of Literature","volume":"60","author":"Yang","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100014","DOI":"10.1016\/j.jtauto.2019.100014","article-title":"The Pathogenesis of Bullous Skin Diseases","volume":"2","author":"Yang","year":"2019","journal-title":"J. Transl. Autoimmun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13739","DOI":"10.1074\/jbc.271.23.13739","article-title":"Demonstration of the Molecular Shape of BP180, a 180-kDa Bullous Pemphigoid Antigen and Its Potential for Trimer Formation","volume":"271","author":"Hirako","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tuusa, J., Kokkonen, N., and Tasanen, K. (2021). BP180\/Collagen XVII: A Molecular View. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212233"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid","volume":"8","author":"Liu","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.16654","article-title":"What\u2019s New in the Pathogeneses and Triggering Factors of Bullous Pemphigoid","volume":"50","author":"Ujiie","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA Using Bacterial Recombinant NC16a Protein as a Diagnostic and Monitoring Tool for Bullous Pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J. Dermatol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.4049\/jimmunol.1001524","article-title":"Ectodomain Shedding Generates Neoepitopes on Collagen XVII, the Major Autoantigen for Bullous Pemphigoid","volume":"185","author":"Nishie","year":"2010","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2019.01454","article-title":"Proteases in Pemphigoid Diseases","volume":"10","author":"Hiroyasu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.brainres.2007.04.073","article-title":"Distribution of Collagen XVII in the Human Brain","volume":"1158","author":"Suuronen","year":"2007","journal-title":"Brain Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00441-012-1368-x","article-title":"Transmembrane Collagen XVII Is a Novel Component of the Glomerular Filtration Barrier","volume":"348","author":"Hurskainen","year":"2012","journal-title":"Cell Tissue Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jid.2016.06.015","article-title":"Bullous Pemphigoid, Neurodegenerative Disease, and Hippocampal BP180 Expression: A Retrospective Postmortem Neuropathologic Study","volume":"136","author":"Barrick","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/08916934.2011.606447","article-title":"Pemphigoid Diseases: Pathogenesis, Diagnosis, and Treatment","volume":"45","author":"Kasperkiewicz","year":"2012","journal-title":"Autoimmunity"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jamadermatol.2018.4390","article-title":"Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid","volume":"155","author":"Meijer","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"912876","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms","volume":"13","author":"Cole","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bjd.14822","article-title":"Complement in Bullous Pemphigoid: Results from a Large Observational Study","volume":"176","author":"Romeijn","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., Holtsche, M.M., Schmidt, E., Hammers, C.M., Zillikens, D., Ludwig, R.J., and Kridin, K. (2020). Presence of Cutaneous Complement Deposition Distinguishes between Immunological and Histological Features of Bullous Pemphigoid\u2014Insights from a Retrospective Cohort Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123928"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00403-021-02253-8","article-title":"Characterizing the Proteome of Bullous Pemphigoid Blister Fluid Utilizing Tandem Mass Tag Labeling Coupled with LC\u2013MS\/MS","volume":"314","author":"Solimani","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3389\/fimmu.2018.02687","article-title":"Complement-Activating Capacity of Autoantibodies Correlates with Disease Activity in Bullous Pemphigoid Patients","volume":"9","author":"Chiorean","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous Pemphigoid Autoantibodies Directly Induce Blister Formation without Complement Activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjd.14411","article-title":"Bullous Pemphigoid Suggestive of Complement-independent Blister Formation with Anti- BP 180 IgG4 Autoantibodies","volume":"175","author":"Dainichi","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fimmu.2018.00407","article-title":"The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury","volume":"9","author":"Fang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2249.2004.02401.x","article-title":"Elevated Expression and Release of Tissue-Type, but Not Urokinase-Type, Plasminogen Activator after Binding of Autoantibodies to Bullous Pemphigoid Antigen 180 in Cultured Human Keratinocytes","volume":"135","author":"Schmidt","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from Patients with Bullous Pemphigoid Depletes Cultured Keratinocytes of the 180-kDa Bullous Pemphigoid Antigen (Type XVII Collagen) and Weakens Cell Attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajpath.2012.11.029","article-title":"Bullous Pemphigoid IgG Induces BP180 Internalization via a Macropinocytic Pathway","volume":"182","author":"Hiroyasu","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 Associated with Bullous Pemphigoid Release Interleukin-6 and Interleukin-8 from Cultured Human Keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jdv.12929","article-title":"Calcitriol Exerts Anti-Inflammatory Effects in Keratinocytes Treated with Autoantibodies from a Patient with Bullous Pemphigoid","volume":"30","author":"Tukaj","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jdermsci.2017.07.012","article-title":"IgG4, Complement, and the Mechanisms of Blister Formation in Pemphigus and Bullous Pemphigoid","volume":"88","author":"Dainichi","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-007-0734-0","article-title":"The Relevance of the IgG Subclass of Autoantibodies for Blister Induction in Autoimmune Bullous Skin Diseases","volume":"299","author":"Sitaru","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-4632.2008.03361.x","article-title":"The Predominance of IgG4 in Prodromal Bullous Pemphigoid","volume":"47","author":"Lamb","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE Autoantibodies to BP180 and BP230 and Their Relationship to Clinical Features in Bullous Pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of Serum Levels of IgE Autoantibodies Against BP180 with Bullous Pemphigoid Disease Activity","volume":"153","author":"Huebner","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3389\/fimmu.2019.02331","article-title":"The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid","volume":"10","author":"Messingham","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1128154","DOI":"10.3389\/fmed.2023.1128154","article-title":"The Cytokine Milieu of Bullous Pemphigoid: Current and Novel Therapeutic Targets","volume":"10","author":"Maglie","year":"2023","journal-title":"Front. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00403-012-1213-9","article-title":"Circulating CD4+ CD25brightFOXP3+ Regulatory T-Cells Are Significantly Reduced in Bullous Pemphigoid Patients","volume":"304","author":"Quaglino","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jdv.12091","article-title":"Regulatory T Cells in Skin Lesions and Blood of Patients with Bullous Pemphigoid","volume":"28","author":"Antiga","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/ced.13135","article-title":"T Regulatory Cells and Other Lymphocyte Subsets in Patients with Bullous Pemphigoid","volume":"42","author":"Gambichler","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdermsci.2020.08.004","article-title":"Regulatory T Cell Subsets in Bullous Pemphigoid and Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid","volume":"100","author":"Muramatsu","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3389\/fimmu.2019.01746","article-title":"Role of Regulatory Immune Cells and Molecules in Autoimmune Bullous Dermatoses","volume":"10","author":"Cao","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3389\/fimmu.2018.00779","article-title":"Humoral Epitope Spreading in Autoimmune Bullous Diseases","volume":"9","author":"Didona","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/jid.2009.309","article-title":"Sequential Intramolecular Epitope Spreading of Humoral Responses to Human BPAG2 in a Transgenic Model","volume":"130","author":"Calabresi","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3389\/fimmu.2019.01410","article-title":"Immune Reaction to Type XVII Collagen Induces Intramolecular and Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models","volume":"10","author":"Ujiie","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/jid.2011.180","article-title":"Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a Prospective Multicenter Study","volume":"131","author":"Calabresi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.tripleo.2009.12.044","article-title":"Lichen Planus Pemphigoides, a Possible Example of Epitope Spreading","volume":"109","author":"Mignogna","year":"2010","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000362208","article-title":"Relationship between Radiation Therapy and Bullous Pemphigoid","volume":"229","author":"Nguyen","year":"2014","journal-title":"Dermatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/tan.12960","article-title":"A Multi-Hit Hypothesis of Bullous Pemphigoid and Associated Neurological Disease: Is HLA-DQB1*03:01, a Potential Link between Immune Privileged Antigen Exposure and Epitope Spreading?","volume":"89","author":"Amber","year":"2017","journal-title":"HLA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archderm.1970.04000080077015","article-title":"Bullous Pemphigoid in an 11-Year-Old Boy","volume":"102","author":"Bean","year":"1970","journal-title":"Arch. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A Method for Estimating the Probability of Adverse Drug Reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt1977213247","article-title":"Toward the Operational Identification of Adverse Drug Reactions","volume":"21","author":"Karch","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjd.15195","article-title":"The Association between Drugs and Bullous Pemphigoid","volume":"176","author":"Tan","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0738-081X(98)00008-X","article-title":"Drug-Induced Pemphigoid: Bullous and Cicatricial","volume":"16","author":"Vassileva","year":"1998","journal-title":"Clin. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-Induced Pemphigoid: A Review of the Literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-Analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2019.12.059","article-title":"Missed Drug-Induced Bullous Pemphigoid Leads to Longer Immunosuppression than Recognized Cases: A 9-Year Retrospective Review","volume":"82","author":"Molina","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-4362.1991.tb03867.x","article-title":"Pemphigus and Bullous Pemphigoid Due to Drugs","volume":"30","author":"Ruocco","year":"1991","journal-title":"Int. J. Dermatol."},{"key":"ref_67","first-page":"171","article-title":"Drug-Induced Bullous Pemphigoid with Positive Patch Test and in Vitro IgE Sensitization","volume":"85","author":"Borch","year":"2005","journal-title":"Acta Derm. Venereol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0190-9622(88)70050-X","article-title":"Bullous Pemphigoid Mimicking Bullous Erythema Multiforme: An Untoward Side Effect of Penicillins","volume":"18","author":"Alcalay","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The Incretin System: Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41574-021-00512-2","article-title":"Type 2 Diabetes Mellitus in Older Adults: Clinical Considerations and Management","volume":"17","author":"Bellary","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl Peptidase-IV Inhibitors Induced Bullous Pemphigoid: A Case Report and Analysis of Cases Reported in the European Pharmacovigilance Database","volume":"41","author":"Aranburu","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous Pemphigoid and Dipeptidyl Peptidase IV Inhibitors: A Case-Noncase Study in the French Pharmacovigilance Database","volume":"175","author":"Moulis","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl Peptidase IV Inhibitors, a Risk Factor for Bullous Pemphigoid: Retrospective Multicenter Case-Control Study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/jdi.12877","article-title":"Dipeptidyl Peptidase-4 Inhibitors-Associated Bullous Pemphigoid: A Retrospective Study of 168 Pemphigoid and 9,304 Diabetes Mellitus Patients","volume":"10","author":"Kawaguchi","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaad.2018.09.048","article-title":"Dipeptidyl-Peptidase IV Inhibitor\u2013Associated Bullous Pemphigoid: A Systematic Review and Meta-Analysis","volume":"85","author":"Kridin","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/jdi.13676","article-title":"Association between Dipeptidyl Peptidase-4 Inhibitors and Increased Risk for Bullous Pemphigoid within 3 Months from First Use: A 5-year Population-based Cohort Study Using the Japanese National Database","volume":"13","author":"Kuwata","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of Dipeptidyl Peptidase 4 Inhibitor Use with Risk of Bullous Pemphigoid in Patients with Diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00403-021-02317-9","article-title":"Dipeptidyl-Peptidase IV Inhibitor (DPP4i) Confers Increased Odds of Bullous Pemphigoid Even Years after Drug Initiation","volume":"315","author":"Kridin","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00403-023-02562-0","article-title":"Prevalence of Diabetes Mellitus in Bullous Pemphigoid Patients in the Absence of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis","volume":"315","author":"Guo","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jaad.2018.05.030","article-title":"Oral Diabetes Medications Other than Dipeptidyl Peptidase 4 Inhibitors Are Not Associated with Bullous Pemphigoid: A Finnish Nationwide Case-Control Study","volume":"79","author":"Varpuluoma","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jaad.2018.06.043","article-title":"Comment on \u201cOral Diabetes Medications Other than Dipeptidyl Peptidase-4 Inhibitors Are Not Associated with Bullous Pemphigoid: A Finnish Nationwide Case Control Study\u201d","volume":"79","author":"Kridin","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1016\/j.jaad.2019.01.086","article-title":"Comment on \u201cOral Diabetes Medications Other than Dipeptidyl Peptidase-4 Inhibitors Are Not Associated with Bullous Pemphigoid: A Finnish Nationwide Case-Control Study\u201d and a Case Report of Glucagon-like Peptide-1 Receptor Agonist\u2013Induced Bullous Pemphigoid","volume":"80","author":"Schwager","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lambadiari, V., Kountouri, A., Kousathana, F., Korakas, E., Kokkalis, G., Theotokoglou, S., Palaiodimou, L., Katsimbri, P., Ikonomidis, I., and Theodoropoulos, K. (2021). The Association of Bullous Pemphigoid with Dipeptidyl-Peptidase 4 Inhibitors: A Ten-Year Prospective Observational Study. BMC Endocr. Disord., 21.","DOI":"10.1186\/s12902-021-00689-7"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2165\/11591400-000000000-00000","article-title":"Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences","volume":"71","author":"Baetta","year":"2011","journal-title":"Drugs"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","article-title":"HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors","volume":"138","author":"Ujiie","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2133.2005.06998.x","article-title":"Bullous Pemphigoid Antigen II (BP180) and Its Soluble Extracellular Domains Are Major Autoantigens in Mucous Membrane Pemphigoid: The Pathogenic Relevance to HLA Class II Alleles and Disease Severity: Circulating Autoantibody Profile of MMP","volume":"154","author":"Oyama","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2340\/00015555-3166","article-title":"Gliptin-Associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4\/CD26 in Bullous Pemphigoid","volume":"99","author":"Lindgren","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12781","article-title":"Cut to the Chase: A Review of CD26\/Dipeptidyl Peptidase-4\u2032s (DPP4) Entanglement in the Immune System","volume":"185","author":"Klemann","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/Dipeptidyl Peptidase IV Enhances CCL11\/Eotaxin-Mediated Recruitment of Eosinophils In Vivo","volume":"181","author":"Forssmann","year":"2008","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Gonzalez-Gronow, M. (2008). Dipeptidyl Peptidase IV (DPP IV\/CD26) Is a Cell-Surface Plasminogen Receptor. Front. Biosci., 13.","DOI":"10.2741\/2785"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3389\/fimmu.2019.01224","article-title":"Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180","volume":"10","author":"Mai","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/jid.2008.424","article-title":"Plasmin Plays a Role in the In Vitro Generation of the Linear IgA Dermatosis Antigen LADB97","volume":"129","author":"Hofmann","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/bjd.16479","article-title":"Unique Clinical and Serological Features of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors","volume":"178","author":"Horikawa","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjd.18516","article-title":"Clinical and Immunological Characterization of 14 Cases of Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: A Single-centre Study","volume":"182","author":"Hayashi","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/ijd.14005","article-title":"Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors. Eight Cases with Clinical and Immunological Characterization","volume":"57","author":"Ishii","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/25785826.2020.1787584","article-title":"A Case of Anti-BP230 Antibody-Positive Bullous Pemphigoid Receiving DPP-4 Inhibitor","volume":"44","author":"Sawada","year":"2021","journal-title":"Immunol. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2017.09.051","article-title":"Detection and Characterization of IgG, IgE, and IgA Autoantibodies in Patients with Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors","volume":"78","author":"Fania","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jdcr.2021.12.021","article-title":"Serum Autoantibodies against the Extracellular Region of A6\u03b24 Integrin in a Patient with Dipeptidyl Peptidase-4 Inhibitor\u2013Induced Bullous Pemphigoid","volume":"20","author":"Yamashita","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjd.16656","article-title":"Detection of Anti-BP180 NC16A Autoantibodies after the Onset of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid: A Report of Three Patients","volume":"179","author":"Mai","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2340\/00015555-3010","article-title":"Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid: Recurrence with Epitope Spreading","volume":"98","author":"Takama","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/bjd.17690","article-title":"Epitope-spreading Phenomena in Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid","volume":"180","author":"Iranzo","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/exd.13459","article-title":"Biomarkers Related to Bullous Pemphigoid Activity and Outcome","volume":"26","author":"Giusti","year":"2017","journal-title":"Exp. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Hung, C.-T., Chang, Y.-L., and Wang, W.-M. (2022). Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214101"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/db17-0934","article-title":"DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring","volume":"67","author":"Long","year":"2018","journal-title":"Diabetes"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0002-9440(10)63762-5","article-title":"Keratinocytes from Patients Lacking Collagen XVII Display a Migratory Phenotype","volume":"164","author":"Tasanen","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/25785826.2019.1619233","article-title":"Dipeptidyl Peptidase IV Inhibitor-Associated Bullous Pemphigoid: A Recently Recognized Autoimmune Blistering Disease with Unique Clinical, Immunological and Genetic Characteristics","volume":"42","author":"Nishie","year":"2019","journal-title":"Immunol. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1084960","DOI":"10.3389\/fimmu.2022.1084960","article-title":"Lisinopril Prevents Bullous Pemphigoid Induced by Dipeptidyl Peptidase 4 Inhibitors via the Mas Receptor Pathway","volume":"13","author":"Nozawa","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40257-020-00563-7","article-title":"More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study","volume":"22","author":"Schmidt","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2125.2007.03031.x","article-title":"The Effect of Age, Gender, and Body Mass Index on the Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Volunteers","volume":"65","author":"He","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Kiny\u00f3, \u00c1., Hanyecz, A., Lengyel, Z., V\u00e1rszegi, D., Ol\u00e1h, P., Gy\u00f6m\u00f6rei, C., K\u00e1lm\u00e1n, E., Berki, T., and Gyulai, R. (2021). Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091916"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1346-8138.14245","article-title":"Decrease in Eosinophils Infiltrating into the Skin of Patients with Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid","volume":"45","author":"Chijiwa","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1684\/ejd.2018.3371","article-title":"\u0392ullous Pemphigoid in Patients with DPP-4 Inhibitors at the Onset of Disease: Does This Differ from Common Bullous Pemphigoid?","volume":"28","author":"Patsatsi","year":"2018","journal-title":"Eur. J. Dermatol. EJD"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e13790","DOI":"10.1111\/dth.13790","article-title":"Dipeptidyl-peptidase IV Inhibitors (DPP4i)-associated Bullous Pemphigoid: Estimating the Clinical Profile and Exploring Intraclass Differences","volume":"33","author":"Kridin","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of Bullous Pemphigoid with Dipeptidyl-Peptidase 4 Inhibitors in Patients with Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-4632.2009.03839.x","article-title":"Medication History of a Series of Patients with Bullous Pemphigoid from Northern Greece\u2014Observations and Discussion","volume":"48","author":"Patsatsi","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1203475420972349","article-title":"Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients","volume":"25","author":"Armanious","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous Adverse Events Caused by Immune Checkpoint Inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1208418","DOI":"10.3389\/fmed.2023.1208418","article-title":"Autoimmune Bullous Dermatoses in Cancer Patients Treated by Immunotherapy: A Literature Review and Italian Multicentric Experience","volume":"10","author":"Merli","year":"2023","journal-title":"Front. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse Cutaneous Toxicities by PD-1\/PD-L1 Immune Checkpoint Inhibitors: Pathogenesis, Treatment, and Surveillance","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint Inhibitor-Associated Bullous Cutaneous Immune-Related Adverse Events: A Multicentre Observational Study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous Disorders Associated with Anti\u2013PD-1 and Anti\u2013PD-L1 Therapy: A Retrospective Analysis Evaluating the Clinical and Histopathologic Features, Frequency, and Impact on Cancer Therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e15466","DOI":"10.1111\/dth.15466","article-title":"Self-resolving Bullous Pemphigoid Induced by Cemiplimab","volume":"35","author":"Molle","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e253059","DOI":"10.1136\/bcr-2022-253059","article-title":"Two Rare Cases of Bullous Pemphigoid Associated with Immune Checkpoint Inhibitors","volume":"15","author":"Mazumder","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of Bullous Pemphigoid with Immune Checkpoint Inhibitor Therapy in Patients with Cancer: A Systematic Review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-Associated Molecular Differences for Cancer Immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e2136823","DOI":"10.1001\/jamanetworkopen.2021.36823","article-title":"Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients with Melanoma","volume":"4","author":"Jang","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/ijd.14742","article-title":"Pruritic Bullous Skin Eruption in a Male Patient Receiving Immunotherapy for Oropharyngeal Cancer","volume":"59","author":"Lee","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"adv00377","DOI":"10.2340\/00015555-3740","article-title":"Bullous Pemphigoid Associated with Anti-Programmed Cell Death Protein 1 and Anti-Programmed Cell Death Ligand 1 Therapy: A Review of the Literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_134","first-page":"2050313X2311609","article-title":"A Case of Drug-Induced Bullous Pemphigoid Secondary to Immunotherapy Treated with Upadacitinib: A Case Report. SAGE Open Med","volume":"11","author":"Gresham","year":"2023","journal-title":"Case Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/cup.13687","article-title":"Neutrophil-predominant Bullous Pemphigoid Induced by Checkpoint Inhibitors: A Case Series","volume":"47","author":"Morris","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1\/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous Pemphigoid after Anti\u2013Programmed Death-1 Therapy: A Retrospective Case-Control Study Evaluating Impact on Tumor Response and Survival Outcomes","volume":"87","author":"Nelson","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of Cutaneous Immune-Related Adverse Events with Increased Survival in Patients Treated with Anti\u2013Programmed Cell Death 1 and Anti\u2013Programmed Cell Death Ligand 1 Therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000081491","article-title":"Interleukin-2-Associated Bullous Drug Dermatosis","volume":"210","author":"Hofmann","year":"2005","journal-title":"Dermatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.jaad.2012.01.034","article-title":"Erlotinib-Induced Bullous Pemphigoid","volume":"67","author":"Stingeni","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/jdv.12662","article-title":"Bullous Pemphigoid Induced by M-TOR Inhibitors in Renal Transplant Recipients","volume":"29","author":"Atzori","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1684\/ejd.2012.1673","article-title":"Bullous Pemphigoid in a Transplant Recipient: Is This a Sign of Allograft Rejection?","volume":"22","author":"Caldarola","year":"2012","journal-title":"Eur. J. Dermatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/ced.13309","article-title":"Dabrafenib-Induced Pemphigoid-like Reaction","volume":"43","author":"Satta","year":"2018","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-021-06169-9","article-title":"Cutaneous Toxicities Occurring during Palbociclib (CDK4\/6 Inhibitor) and Endocrine Therapy in Patients with Advanced Breast Cancer: A Single-Centre Experience","volume":"188","author":"Chawla","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous Pemphigoid Induced by Biologic Drugs in Psoriasis: A Systematic Review","volume":"33","author":"Steinhoff","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1050373","DOI":"10.3389\/fimmu.2022.1050373","article-title":"Paradoxical Phenomena of Bullous Pemphigoid Induced and Treated by Identical Biologics","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New Insights into the Pathogenesis of Bullous Pemphigoid: 2019 Update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/000155599750010689","article-title":"Blister Fluid Cytokines in Cutaneous Inflammatory Bullous Disorders","volume":"79","author":"Rhodes","year":"1999","journal-title":"Acta Derm Venereol."},{"key":"ref_150","first-page":"148","article-title":"Bullous Pemphigoid and Pemphigus Vulgaris: Correlated Behaviour of Serum VEGF, sE-Selectin and TNF-Alpha Levels","volume":"11","author":"Ameglio","year":"1997","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.4049\/jimmunol.179.7.4840","article-title":"Generation of Th1 and Th2 Chemokines by Human Eosinophils: Evidence for a Critical Role of TNF-\u03b1","volume":"179","author":"Liu","year":"2007","journal-title":"J. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1197273","DOI":"10.3389\/fmed.2023.1197273","article-title":"Pyoderma Gangrenosum Following Anti-TNF Therapy in Chronic Recurrent Multifocal Osteomyelitis: Drug Reaction or Cutaneous Manifestation of the Disease? A Critical Review on the Topic with an Emblematic Case Report","volume":"10","author":"Romagnuolo","year":"2023","journal-title":"Front. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased Expression of Th2-Associated Chemokines in Bullous Pemphigoid Disease. Role of Eosinophils in the Production and Release of These Chemokines","volume":"120","author":"Wellemans","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1111\/1346-8138.13909","article-title":"Development of Bullous Pemphigoid during Secukinumab Treatment for Psoriasis","volume":"44","author":"Ho","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fimmu.2019.00701","article-title":"NET Formation in Bullous Pemphigoid Patients with Relapse Is Modulated by IL-17 and IL-23 Interplay","volume":"10","author":"Giusti","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Maronese, C.A., Cassano, N., Genovese, G., Foti, C., Vena, G.A., and Marzano, A.V. (2022). The Intriguing Links between Psoriasis and Bullous Pemphigoid. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010328"},{"key":"ref_157","first-page":"360","article-title":"Bullous Pemphigoid Induced by Hydrochlorothiazide Therapy","volume":"13","author":"Warner","year":"2014","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/1346-8138.14741","article-title":"Analysis of Patients with Drug-induced Pemphigoid Using the Japanese Adverse Drug Event Report Database","volume":"46","author":"Tanaka","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The Associations Between Bullous Pemphigoid and Drug Use: A UK Case-Control Study","volume":"149","author":"Chi","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1684\/ejd.2009.0715","article-title":"Brunsting-Perry Type Localized Bullous Pemphigoid, Possibly Induced by Furosemide Administration and Sun Exposure","volume":"19","author":"Takeichi","year":"2009","journal-title":"Eur. J. Dermatol."},{"key":"ref_161","first-page":"562","article-title":"Furosemide-Induced Bullous Pemphigoid: Case Report and Review of Literature","volume":"5","author":"Lee","year":"2006","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_162","first-page":"e20647","article-title":"A Case of Drug-Induced Bullous Pemphigoid with an Isomorphic Response and Updated Review of Koebnerization in Bullous Diseases","volume":"13","author":"Ambur","year":"2021","journal-title":"Cureus"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1046\/j.1365-2133.1998.02146.x","article-title":"Bonnetblanc Bullous Pemphigoid Induced by Bumetanide","volume":"138","author":"Boulinguez","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jdcr.2022.06.023","article-title":"A Case of Bullous Pemphigoid Induced by Torsemide","volume":"26","author":"Wurtz","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.semerg.2012.02.002","article-title":"Penfigoide ampolloso inducido por hidroclorotiazida","volume":"39","year":"2013","journal-title":"SEMERGEN\u2014Med. Fam."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1684\/ejd.2020.3773","article-title":"Acetazolamide: A New Trigger for Bullous Pemphigoid?","volume":"30","author":"Cozzani","year":"2020","journal-title":"Eur. J. Dermatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2019.02.017","article-title":"Drugs Used for Neurologic and Psychiatric Conditions Increase the Risk for Bullous Pemphigoid: A Case\u2013Control Study","volume":"81","author":"Varpuluoma","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"102157","DOI":"10.1016\/j.msard.2020.102157","article-title":"A Case of Drug-Induced Bullous Pemphigoid Associated with Teriflunomide: A Patient with Relapsing Multiple Sclerosis","volume":"43","author":"Arslan","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.jaad.2019.03.091","article-title":"Bullous Pemphigoid and Neuropsychiatric Medications: An Influence of Drugs or of Underlying Conditions?","volume":"88","author":"Kridin","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1111\/bcp.13737","article-title":"Lisinopril-associated Bullous Pemphigoid in an Elderly Woman: A Case Report of a Rare Adverse Drug Reaction","volume":"84","author":"Ballout","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-4362.1992.tb01383.x","article-title":"Enalapril: A Powerful in Vitro Non-Thiol Acantholytic Agent","volume":"31","author":"Angelis","year":"1992","journal-title":"Int. J. Dermatol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/106002808902300115","article-title":"Bullous Pemphigoid Associated with Captopril","volume":"23","author":"Mallet","year":"1989","journal-title":"DICP"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2230.2007.02603.x","article-title":"A Biological Approach in a Patient with Psoriasis and Bullous Pemphigoid Associated with Losartan Therapy","volume":"33","author":"Saraceno","year":"2008","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1002\/hsr2.452","article-title":"Valsartan-associated Bullous Pemphigoid Initially Presenting as Erythema Multiforme","volume":"4","author":"Gao","year":"2021","journal-title":"Health Sci. Rep."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-4632.2009.04417.x","article-title":"Amlodipine-Associated Bullous Pemphigoid with Erythema Multiforme-like Clinical Features: Correspondence","volume":"50","author":"Park","year":"2011","journal-title":"Int. J. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2133.2000.03389.x","article-title":"Pemphigoid Nodularis Associated with Nifedipine","volume":"142","author":"Ameen","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-4362.1999.00601.x","article-title":"Pemphigus and Pemphigoid-like Effects of Nifedipine on in Vitro Cultured Normal Human Skin Explants: Pemphigus and Pemphigoid-like Effects of Nifedipine","volume":"38","author":"Brenner","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1111\/jdv.16243","article-title":"Drugs Associated with Bullous Pemphigoid: Role of H\u039cG- CO a Reductase Inhibitors","volume":"34","author":"Papadopoulou","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdin.2021.02.002","article-title":"The Association between Statins and Subsequent Risk of Bullous Pemphigoid: A Population-Based Cohort Study","volume":"3","author":"Chang","year":"2021","journal-title":"JAAD Int."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1346-8138.2012.01636.x","article-title":"Case of Drug-Induced Bullous Pemphigoid by Levofloxacin","volume":"39","author":"Ma","year":"2012","journal-title":"J. Dermatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e1202","DOI":"10.1097\/MJT.0000000000000283","article-title":"Ciprofloxacin as a Trigger for Bullous Pemphigoid: The Second Case in the Literature","volume":"23","author":"Cozzani","year":"2016","journal-title":"Am. J. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16786\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:30:52Z","timestamp":1760131852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,26]]},"references-count":181,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242316786"],"URL":"https:\/\/doi.org\/10.3390\/ijms242316786","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,26]]}}}